Do All Critically Ill Patients with COVID-19 Disease Benefit from Adding Tocilizumab to Glucocorticoids? A Retrospective Cohort Study.

Autor: Mussini, Cristina1,2 (AUTHOR) cristina.mussini@unimore.it, Cozzi-Lepri, Alessandro3 (AUTHOR), Meschiari, Marianna1 (AUTHOR), Franceschini, Erica1 (AUTHOR), Burastero, Giulia2 (AUTHOR), Faltoni, Matteo2 (AUTHOR), Franceschi, Giacomo1 (AUTHOR), Iadisernia, Vittorio2 (AUTHOR), Volpi, Sara2 (AUTHOR), Dessilani, Andrea2 (AUTHOR), Gozzi, Licia1 (AUTHOR), Conti, Jacopo2 (AUTHOR), Del Monte, Martina2 (AUTHOR), Milic, Jovana2,4 (AUTHOR), Borghi, Vanni2 (AUTHOR), Tonelli, Roberto4,5 (AUTHOR), Brugioni, Lucio6 (AUTHOR), Romagnoli, Elisa6 (AUTHOR), Pietrangelo, Antonello7 (AUTHOR), Corradini, Elena7 (AUTHOR)
Zdroj: Viruses (1999-4915). Feb2023, Vol. 15 Issue 2, p294. 13p.
Databáze: Academic Search Ultimate
Nepřihlášeným uživatelům se plný text nezobrazuje